Why the study?
Does anticoagulant therapy prevent thromboembolic events in patients with class II-III congestive heart failure?
Does anticoagulant therapy prevent thromboembolic events in patients with class II-III congestive heart failure?
Due to the lack of controlled studies, well-founded recommendations for anticoagulant therapy in patients with class II-III congestive heart failure cannot be made despite a 1.6-3.5% annual risk of thromboembolism.
Answers are grounded in this paper and cite their sources.
Risk of thromboembolism in class II-III HF persists despite anticoagulation; leaves open optimal antithrombotic management pending controlled studies.
The incidence of thromboembolic events in unselected patients with class II-III congestive heart failure is 1.6-3.5% per year. Marked limitation of exercise capacity and the presence of echocardiographic left ventricular thrombus appear to be associated with an increased risk of thromboembolism. Several studies have reported that anticoagulant therapy does not eliminate the occurrence of thromboembolism. Because the benefit and risks of anticoagulant therapy in patients with congestive heart failure have not been examined in controlled studies, it is difficult to make well-founded recommendations.
No takes yet. Share an insight, caveat, or question.
W. Bruce Dunkman (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: